Even Two Doses of COVID-19 Vaccine Afforded Some Protection to Immunocompromised Patients

While serologic responses to SARS-CoV-2 vaccination are diminished in certain immunocompromised patients, early studies indicate significant protection against symptomatic COVID-19.

Immunosuppressed patients have impaired ability to generate SARS-CoV-2 antibodies in response to vaccination. While antibody levels may predict risk for symptomatic infection, further data on risk for severe COVID-19 in immunocompromised patients are urgently needed. Now, two studies employ different methods to address that question.

Researchers used data from 21 hospitals in 18 states to assess COVID-19 vaccine effectiveness (VE) in 1194 patients hospitalized with COVID-19 (cases) compared with 1895 hospitalized patients without COVID-19 (controls). In all, 12% of cases and 52% of controls were fully vaccinated, and 21% of the cohort were immunocompromised (primarily solid-organ transplant recipients [SOTRs] and patients with active cancer)…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Even Two Doses of COVID-19 Vaccine Afforded Some Protection to Immunocompromised Patients

Topics

Reviewing Author